Korro Bio receives European Medicines Agency granted ODD for KRRO-110

Korro Bio (KRRO) announced that it has been granted orphan drug designation, ODD, by the European Medicines Agency, EMA, Committee, who adopted a positive opinion on KRRO-110, Korro’s investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency, AATD. “The EMA orphan drug designation for KRRO-110 is a significant milestone for Korro and highlights an urgent need to bring innovative solutions to people with AATD seeking new, disease-modifying therapies,” said Kemi Olugemo, MD, Chief Medical Officer at Korro. “Backed by encouraging preclinical data, KRRO-110 has best-in-class potential for the treatment of AATD. This designation represents an important step toward bringing KRRO-110 to European patients.”